Prelude Therapeutics, Inc. (PRLD)
3.23
-0.09
(-2.71%)
USD |
NASDAQ |
Oct 16, 09:36
Prelude Therapeutics Research and Development Expense (Quarterly) : 16.13M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 16.13M |
| March 31, 2026 | 13.60M |
| December 31, 2025 | 17.99M |
| September 30, 2025 | 21.71M |
| June 30, 2025 | 25.78M |
| March 31, 2025 | 28.82M |
| December 31, 2024 | 31.62M |
| September 30, 2024 | 29.46M |
| June 30, 2024 | 29.51M |
| March 31, 2024 | 27.41M |
| December 31, 2023 | 30.33M |
| September 30, 2023 | 26.26M |
| June 30, 2023 | 24.97M |
| March 31, 2023 | 21.83M |
| Date | Value |
|---|---|
| December 31, 2022 | 25.87M |
| September 30, 2022 | 22.89M |
| June 30, 2022 | 21.31M |
| March 31, 2022 | 22.82M |
| December 31, 2021 | 25.18M |
| September 30, 2021 | 22.72M |
| June 30, 2021 | 22.41M |
| March 31, 2021 | 16.47M |
| December 31, 2020 | 14.57M |
| September 30, 2020 | 15.29M |
| June 30, 2020 | 9.776M |
| March 31, 2020 | 8.536M |
| December 31, 2019 | 8.849M |
| September 30, 2019 | 5.49M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Q32 Bio, Inc. | 4.259M |
| Intellia Therapeutics, Inc. | 80.50M |
| Twist Bioscience Corp. | 18.02M |
| Beam Therapeutics, Inc. | 95.10M |
| Revolution Medicines, Inc. | 392.47M |